Prescribe Cosentyx as your first-line biologic to give you confidence in lasting clear skin for your adult psoriasis patients

Superior results with Cosentyx

At week 16:

Cosentyx helps 21% more patients achieve almost clear skin vs. ustekinumab (P<0.0001)1

**P<0.0001 vs ustekinumab. Adapted from Thaçi D et al. 2015.Study details: Global, multicenter, randomized, double-blind, active comparator, parallel group, superiority phase 3b trial directly comparing the safety and efficacy of Cosentyx with ustekinumab in patients with moderate-to-severe plaque psoriasis. Primary endpoint: PASI 90 response at week 16; 57.6% with ustekinumab (n=335) vs 79.0% with Cosentyx 300mg (n=334, P<0.0001). At week 16, the Cosentyx adverse event profile was similar to ustekinumab. Statistical analysis: Missing values with respect to response variables based on PASI and IGA mod 2011 scores were imputed as nonresponse (nonresponder imputation).

Confidence in lasting clear skin

Cosentyx maintains almost 100% of PASI 90 & PASI 100 response rates from year 1 to year 43

Adapted from Bissonnette R et al. 2016. Data as observed: only subjects with observed data endpoints are included in the efficacy analysis. The above graph displays data from Cosentyx 300 mg fixed interval dosing arm of the SCULPTURE extension study.

Comparable safety profile

Cosentyx has a comparable safety profile to etanercept and ustekinumab at week 524,5

No increase in adverse events over time, seen for between 1 to 4 years3

Image of a person smiling
Cosentyx is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy6 Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate6


  1. Thaçi D, et al. J Am Acad Dermatol 2015; 73(3): 400–409.
  2. McInnes IB, et al. Poster presented at Rheumatology 2017, 25-27 April, 2017, Birmingham, United Kingdom. Poster number 072.
  3. Bissonnette R, et al. Secukinumab demonstrates sustained high efficacy and a favorable safety profile in moderate to severe psoriasis patients through 4 years of treatment. Oral presentation given at the 25th EADV Congress, 28 September–2 October 2016.
  4. Blauvelt A, et al. J Am Acad Dermatol 2017; 76(1): 60–69.
  5. Langley RG, et al. N Engl J Med 2014; 371(4): 326–338.
  6. Cosentyx Summary of Product Characteristics.

COS17-C172 August 2017